MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, ANTX had $33,546K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$33,546K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuance of common...
    • Proceeds from issuance of pre-fu...
    • Maturities of investments
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Purchases of investments
    • Accrued compensation
    • Others

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-10,028 -8,710 -9,353 -17,111
Stock-based compensation expense
1,460 1,400 801 4,045
Net accretion of discount on investments
81 117 211 742
Prepaid expenses and other assets
267 -159 -2,513 1,160
Accounts payable
-405 795 113 -1,204
Accrued compensation
-1,805 674 545 -477
Accrued liabilities
-285 -653 -249 -1,500
Other current liabilities
-662 1,046 -534 -74
Other non-current liabilities
-170 --
Net cash used in operating activities
-12,073 -5,236 -6,375 -18,223
Purchases of investments
2,703 8,326 3,890 33,973
Maturities of investments
10,993 15,500 10,000 49,000
Net cash provided by investing activities
8,290 7,174 6,110 15,027
Proceeds from issuance of common stock in the 2026 private placement, net of placement agent fees and other offering costs
21,894 ---
Proceeds from issuance of pre-funded warrants in the 2026 private placement, net of placement agent fees and other offering costs
15,372 ---
Proceeds from issuance of common stock under the espp
39 0 48 38
Proceeds from exercise of stock options
24 0 0 27
Net cash provided by financing activities
37,329 0 48 65
Net increase (decrease) in cash and cash equivalents
33,546 1,938 -217 -3,131
Cash and cash equivalents at the beginning of the period
19,941 18,003 21,351 -
Cash and cash equivalents at the end of the period
53,487 19,941 18,003 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock in the 2026...$21,894K Proceeds from issuance ofpre-funded warrants in the...$15,372K Proceeds from issuance ofcommon stock under the...$39K Proceeds from exercise ofstock options$24K Maturities of investments$10,993K Net cash provided byfinancing activities$37,329K Net cash provided byinvesting activities$8,290K Canceled cashflow$2,703K Net increase(decrease) in cash and cash...$33,546K Canceled cashflow$12,073K Stock-based compensationexpense$1,460K Purchases of investments$2,703K Net cash used inoperating activities-$12,073K Canceled cashflow$1,460K Net loss-$10,028K Accrued compensation-$1,805K Other currentliabilities-$662K Accounts payable-$405K Accrued liabilities-$285K Prepaid expenses andother assets$267K Net accretion ofdiscount on investments$81K

AN2 Therapeutics, Inc. (ANTX)

AN2 Therapeutics, Inc. (ANTX)